Novel pharmacological treatment strategies for posttraumatic stress disorder

References

• Cantor C. Post-traumatic stress disorder: evolutionary perspectives. Aust N Z J Psychiatry. 2009;43(11):1038–1048. DOI:10.1080/00048670903270407
   PubMed Web of Science ®Google Scholar
• Morrison FG, Ressler KJ. From the neurobiology of extinction to improved clinical treatments. Depress Anxiety. 2014;31(4):279–290. DOI:10.1002/da.22214
   PubMed Web of Science ®Google Scholar
• Yehuda RMcFarlane AC. Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis. Am J Psychiatry. 1995;152(12):1705–1713. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8526234
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Benjet C, Bromet E, Karam EG, et al. The epidemiology of traumatic event exposure worldwide: results from the World Mental Health Survey Consortium. Psychol Med. 2016;46(2):327–343. DOI:10.1017/S0033291715001981
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. DOI:10.1001/archpsyc.62.6.593
   PubMed Web of Science ®Google Scholar
• Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51:1137–1148. DOI:10.1007/s00127-016-1208-5
   PubMed Web of Science ®Google Scholar
• Atwoli L, Stein DJ, Koenen KC, et al. Epidemiology of posttraumatic stress disorder: prevalence, correlates and consequences. Curr Opin Psychiatry. 2015;28(4):307–311. DOI:10.1097/YCO.0000000000000167
   PubMed Web of Science ®Google Scholar
• Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry. 2000;61(Suppl 5):4–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10761674
   PubMed Web of Science ®Google Scholar
• Friedman MJ. PTSD in the DSM-5: reply to Brewin (2013), Kilpatrick (2013), and Maercker and Perkonigg (2013). J Trauma Stress. 2013;26(5):567–569. DOI:10.1002/jts.21847
   PubMed Web of Science ®Google Scholar
• Zoellner LA, Rothbaum BO, Feeny NC. PTSD not an anxiety disorder? DSM committee proposal turns back the hands of time. Depress Anxiety. 2011;28(10):853–856. DOI:10.1002/da.20899
   PubMed Web of Science ®Google Scholar
• Schmidt U. A plea for symptom-based research in psychiatry. Eur J Psychotraumatol. 2015;6:27660. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4439426&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Yehuda R, Hoge CW, McFarlane AC, et al. Post-traumatic stress disorder. Nat Rev Dis Primers. 2015;1:15057. DOI:10.1038/nrdp.2015.57
   PubMed Web of Science ®Google Scholar
• Bailey CR, Cordell E, Sobin SM, et al. Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment. CNS Drugs. 2013;27(3):221–232. DOI:10.1007/s40263-013-0051-4
   PubMed Web of Science ®Google Scholar
• Herman JP, McKlveen JM, Ghosal S, et al. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016;6(2):603–621. DOI:10.1002/cphy.c150015
   PubMed Web of Science ®Google Scholar
• Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun. 2007;21(3):259–272. DOI:10.1016/j.bbi.2006.11.006
   PubMed Web of Science ®Google Scholar
• Resnick HS, Yehuda R, et al. Effect of previous trauma on acute plasma cortisol level following rape. Am J Psychiatry. 1995;152(11):1675–1677. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7485635
   Google Scholar
• Conrad CD. Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability hypothesis. Rev Neurosci. 2008;19(6):395–411. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2746750&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Knoops AJG, Gerritsen L, Van Der Graaf Y, et al. Basal hypothalamic pituitary adrenal axis activity and hippocampal volumes: the SMART-Medea study. Biol Psychiatry. 2010;67(12):1191–1198. DOI:10.1016/j.biopsych.2010.01.025
   PubMed Web of Science ®Google Scholar
• Pitman RK, Rasmusson AM, Koenen KC, et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci. 2012;13(11):769–787. DOI:10.1038/nrn3339
   PubMed Web of Science ®Google Scholar
• Pitman RK, Gilbertson MW, Gurvits TV, et al. Harvard/VA PTSD Twin Study Investigators. Clarifying the origin of biological abnormalities in PTSD through the study of identical twins discordant for combat exposure. Ann N Y Acad Sci. 2006;1071:242–254. DOI:10.1196/annals.1364.019
   PubMed Web of Science ®Google Scholar
• Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron. 2005;48(2):175–187. DOI:10.1016/j.neuron.2005.09.025
   PubMed Web of Science ®Google Scholar
• Sotres-Bayon F, Cain CK, LeDoux JE. Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biol Psychiatry. 2006;60(4):329–336. DOI:10.1016/j.biopsych.2005.10.012
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Radulescu E. Finding the elusive psychiatric “lesion” with 21st-century neuroanatomy: a note of caution. Am J Psychiatry. 2016;173(1):27–33. DOI:10.1176/appi.ajp.2015.15060753
   PubMed Web of Science ®Google Scholar
• Howlett JR, Stein MB. Prevention of trauma and stressor-related disorders: a review. Neuropsychopharmacology. 2016;41(1):357–369. DOI:10.1038/npp.2015.261
   PubMed Web of Science ®Google Scholar
• Bowers ME, Ressler KJ. An overview of translationally informed treatments for posttraumatic stress disorder: animal models of Pavlovian fear conditioning to human clinical trials. Biol Psychiatry. 2015;78(5):E15–E27. DOI:10.1016/j.biopsych.2015.06.008
   Google Scholar
• Valentino RJ, Van Bockstaele E. Endogenous opioids: the downside of opposing stress. Neurobiol Stress. 2015;1:23–32. DOI:10.1016/j.ynstr.2014.09.006
   PubMedGoogle Scholar
• Sherin JE, Nemeroff CB. Post-traumatic stress disorder: the neurobiological impact of psychological trauma. Dialogues Clin Neurosci. 2011;13(3):263–278. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3182008&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• Maren S, Holmes A. Stress and fear extinction. Neuropsychopharmacology. 2016;41(1):58–79. DOI:10.1038/npp.2015.180
   PubMed Web of Science ®Google Scholar
• Nishi D, Hashimoto KNoguchi H, et al. Glutamatergic system abnormalities in posttraumatic stress disorder. Psychopharmacology (Berl). 2015;232(23):4261-4268. doi: 10.1007/s00213-015-4052-5.
   Google Scholar
• Riaza Bermudo-Soriano CPerez-Rodriguez MM, et al. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav. 2012;100(4):752–774. doi: 10.1016/j.pbb.2011.04.010.
   PubMed Web of Science ®Google Scholar
• Levenson J, Weeber E, Selcher JC, et al. Long-term potentiation and contextual fear conditioning increase neuronal glutamate uptake. Nat Neurosci. 2002;5(2):155–161. DOI:10.1038/nn791
   PubMed Web of Science ®Google Scholar
• Almli LM, Fani N, Smith AK, et al. Genetic approaches to understanding post-traumatic stress disorder. Int J Neuropsychopharmacol. 2014;17(2):355–370. DOI:10.1017/S1461145713001090
   PubMed Web of Science ®Google Scholar
• Binder EB, Bradley RG, Liu W, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA. 2008;299(11):1291–1305. DOI:10.1001/jama.299.11.1291
   PubMed Web of Science ®Google Scholar
• Zannas AS, Wiechmann T, Gassen NC, et al. Gene-stress-epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology. 2016;41(1):261–274. DOI:10.1038/npp.2015.235
   PubMed Web of Science ®Google Scholar
• Nugent NR, Lally MA, Brown L, et al. OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV. AIDS Behav. 2012;16(8):2171–2180. DOI:10.1007/s10461-011-0095-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Benedek DM, Fullerton CS, et al. PTSD risk is associated with BDNF Val66Met and BDNF overexpression. Mol Psychiatry. 2014;19(1):8–10. DOI:10.1038/mp.2012.180
   PubMed Web of Science ®Google Scholar
• Bruenig D, Lurie J, Morris CP, et al. A case-control study and meta-analysis reveal BDNF Val66Met is a possible risk factor for PTSD. Neural Plast. 2016;2016:6979435. DOI:10.1155/2016/6979435
   PubMed Web of Science ®Google Scholar
• Charney DS, Deutch AY, Krystal JH, et al. Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry. 1993;50(4):295–305. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8466391
   PubMed Web of Science ®Google Scholar
• Weathers FW, Blake DD, Schnurr PP, et al. The clinician-administered PTSD scale for DSM-5 (CAPS-5). 2013.  Interview available from the National Center for PTSD at www.ptsd.va.gov.
   Google Scholar
• Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1. DOI:10.1186/1471-244X-14-S1-S1
   PubMed Web of Science ®Google Scholar
• Cusack K, Jonas DE, Forneris CA, et al. Psychological treatments for adults with posttraumatic stress disorder: a systematic review and meta-analysis. Clin Psychol Rev. 2016;43:128–141. DOI:10.1016/j.cpr.2015.10.003
   PubMed Web of Science ®Google Scholar
• Lee DJ, Schnitzlein CW, Wolf JP, et al. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33:792–806. DOI:10.1002/da.22511
   PubMed Web of Science ®Google Scholar
• Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;12:CD003388. DOI:10.1002/14651858.CD003388.pub4
   Google Scholar
• Levy-Gigi E, Szabó C, Kelemen O, et al. Association among clinical response, hippocampal volume, and FKBP5 gene expression in individuals with posttraumatic stress disorder receiving cognitive behavioral therapy. Biol Psychiatry. 2013;74(11):793–800. DOI:10.1016/j.biopsych.2013.05.017
   PubMed Web of Science ®Google Scholar
• Brooks SJ, Stein DJ. A systematic review of the neural bases of psychotherapy for anxiety and related disorders. Dialogues Clin Neurosci. 2015;17(3):261–279. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4610611&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Novo Navarro P, Landin-Romero R, Guardiola-Wanden-Berghe R, et al. 25 years of eye movement desensitization and reprocessing (EMDR): the EMDR therapy protocol, hypotheses of its mechanism of action and a systematic review of its efficacy in the treatment of post-traumatic stress disorder. Rev Psiquiatr Salud Ment. 2016. DOI:10.1016/j.rpsm.2015.12.002
   Google Scholar
• Shapiro F. The role of eye movement desensitization and reprocessing (EMDR) therapy in medicine: addressing the psychological and physical symptoms stemming from adverse life experiences. Perm J. 2014;18(1):71–77. DOI:10.7812/TPP/13-098
   PubMedGoogle Scholar
• Pagani M, Di Lorenzo G, Verardo AR, et al. Neurobiological correlates of EMDR monitoring - an EEG study. PLoS One. 2012;7(9):e45753. DOI:10.1371/journal.pone.0045753
   Web of Science ®Google Scholar
• Bandelow B, Sher L, Bunevicius R, et al., WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84. DOI:10.3109/13651501.2012.667114
   PubMed Web of Science ®Google Scholar
• Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012;15(6):825–840. DOI:10.1017/S1461145711001209
   PubMed Web of Science ®Google Scholar
• Hoskins M, Pearce J, Bethell A, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015;206(2):93–100. DOI:10.1192/bjp.bp.114.148551
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr. 2009;14(1 Suppl 1):25–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19169191
   PubMed Web of Science ®Google Scholar
• Albert PR, Vahid-Ansari F, Luckhart C. Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor expression. Front Behav Neurosci. 2014;8:199. DOI:10.3389/fnbeh.2014.00199
   PubMed Web of Science ®Google Scholar
• MacNamara A, Rabinak CA, Kennedy AE, et al. Emotion regulatory brain function and SSRI treatment in PTSD: neural correlates and predictors of change. Neuropsychopharmacology. 2016;41(2):611–618. DOI:10.1038/npp.2015.190
   PubMed Web of Science ®Google Scholar
• Amos TStein DJ, Ipser jc. pharmacological interventions for preventing post-traumatic stress disorder (ptsd). Cochrane database Syst Rev. 2014;(7):CD006239. doi: 10.1002/14651858.CD006239.pub2.
   Google Scholar
• Hurlemann R, Walter H, Rehme AK, et al. Human amygdala reactivity is diminished by the β-noradrenergic antagonist propranolol. Psychol Med. 2010;40(11):1839–1848. DOI:10.1017/S0033291709992376
   PubMed Web of Science ®Google Scholar
• Dębiec J, Bush DEA, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats–a possible mechanism for the persistence of traumatic memories in PTSD. Depress Anxiety. 2011;28(3):186–193. doi:10.1002/da.20803.
   PubMed Web of Science ®Google Scholar
• Villain H, Benkahoul A, Drougard A, et al. Effects of Propranolol, a β-noradrenergic antagonist, on memory consolidation and reconsolidation in mice. Front Behav Neurosci. 2016;10:49. doi:10.3389/fnbeh.2016.00049.
   PubMed Web of Science ®Google Scholar
• Lonergan MH, Olivera-Figueroa LA, Pitman RK, et al. Propranolol’s effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis. J Psychiatry Neurosci. 2013;38(4):222–231. doi:10.1503/jpn.120111.
   PubMed Web of Science ®Google Scholar
• Burbiel JC. Primary prevention of posttraumatic stress disorder: drugs and implications. Mil Med Res. 2015;2:24. doi:10.1186/s40779-015-0053-2.
   PubMedGoogle Scholar
• Steenen SA, van Wijk AJ, van der Heijden GJMG, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol. 2016;30(2):128–139. doi:10.1177/0269881115612236.
   PubMed Web of Science ®Google Scholar
• Fallowfield JM, Marlow HF. Propranolol is contraindicated in asthma. BMJ. 1996;313(7070):1486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8973266. Accessed June 26, 2016.
   Google Scholar
• Belkin MR, Schwartz TL. Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. Drugs Context. 2015;4:212286. doi:10.7573/dic.212286.
   PubMedGoogle Scholar
• Gamache K, Pitman RK, Nader K. Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder. Neuropsychopharmacology. 2012;37(13):2789–2796. DOI:10.1038/npp.2012.145
   PubMed Web of Science ®Google Scholar
• Connor DF, Grasso DJ, Slivinsky MD, et al. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. J Child Adolesc Psychopharmacol. 2013;23(4):244–251. DOI:10.1089/cap.2012.0119
   PubMed Web of Science ®Google Scholar
• Groeneweg FL, Karst H, de Kloet ER, et al. Rapid non-genomic effects of corticosteroids and their role in the central stress response. J Endocrinol. 2011;209(2):153–167. doi:10.1530/JOE-10-0472.
   PubMed Web of Science ®Google Scholar
• van Zuiden M, Kavelaars A, Geuze E,et al. Predicting PTSD: pre-existing vulnerabilities in glucocorticoid-signaling and implications for preventive interventions. Brain Behav Immun. 2013;30:12–21. doi:10.1016/j.bbi.2012.08.015.
   PubMed Web of Science ®Google Scholar
• Yehuda R, Bierer LM, Schmeidler J, et al. Low cortisol and risk for PTSD in adult offspring of holocaust survivors. Am J Psychiatry. 2000;157(8):1252–1259. doi:10.1176/appi.ajp.157.8.1252.
   PubMed Web of Science ®Google Scholar
• Zohar J, Juven-Wetzler A, Sonnino R, et al. New insights into secondary prevention in post-traumatic stress disorder. Dialogues Clin Neurosci. 2011;13(3):301–309. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22033784
   PubMedGoogle Scholar
• Yehuda R, Bierer LM, Pratchett LC, et al. Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: randomized trial showing improved treatment retention and outcome. Psychoneuroendocrinology. 2015;51:589–597. DOI:10.1016/j.psyneuen.2014.08.004
   PubMed Web of Science ®Google Scholar
• Zohar J, Yahalom H, Kozlovsky N, et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies. Eur Neuropsychopharmacol. 2011;21(11):796–809. DOI:10.1016/j.euroneuro.2011.06.001
   PubMed Web of Science ®Google Scholar
• Delahanty DL, Gabert-Quillen C, Ostrowski SA, et al. The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial. CNS Spectr. 2013;18(2):103–111. DOI:10.1017/S1092852913000096
   PubMed Web of Science ®Google Scholar
• Phillips KM, Clark ME, et al. Pain and psychiatric comorbidities among two groups of Iraq and Afghanistan era Veterans. J Rehabil Res Dev. 2016 Jan;53(4):413–432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27532156
   Google Scholar
• Bali A, Randhawa PK, Jaggi AS. Stress and opioids: role of opioids in modulating stress-related behavior and effect of stress on morphine conditioned place preference. Neurosci Biobehav Rev. 2015;51:138–150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25636946
   Google Scholar
• Barfield ET, Moser VA, Hand A, et al. β-endorphin modulates the effect of stress on novelty-suppressed feeding. Front Behav Neurosci. 2013; 7:19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23503677
   Google Scholar
• Joshi JC, Ray A, Gulati K. Differential modulatory effects of morphine on acute and chronic stress induced neurobehavioral and cellular markers in rats. Eur J Pharmacol. 2014;729:17–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24508522
   Google Scholar
• Holbrook TL, Galarneau MR, Dye JL, et al. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010;362(2):110–117. DOI:10.1056/NEJMoa0903326
   PubMed Web of Science ®Google Scholar
• Suliman S, Seedat S, Pingo J, et al. Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial. BMC Psychiatry. 2015;15:24. DOI:10.1186/s12888-015-0391-3
   PubMed Web of Science ®Google Scholar
• Stoddard FJ, Luthra R, Sorrentino EA, et al. A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol. 2011;21(5):469–477. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22040192
   Google Scholar
• Sijbrandij M, Kleiboer A, Bisson JI, et al. Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. The Lancet Psychiatry. 2015;2(5):413–421. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26360285
   Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571–3580. DOI:10.1017/S0033291715001506
   PubMed Web of Science ®Google Scholar
• Zhang L-M, Zhou -W-W, Ji Y-J, et al. Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder. Psychopharmacology. 2015;232(4):663–672. DOI:10.1007/s00213-014-3697-9
   PubMed Web of Science ®Google Scholar
• Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681–688. DOI:10.1001/jamapsychiatry.2014.62
   PubMed Web of Science ®Google Scholar
• Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci. 2009;11(3):239–255. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19877493
   PubMedGoogle Scholar
• Su S, Xiao Z, Lin Z, et al. Plasma brain-derived neurotrophic factor levels in patients suffering from post-traumatic stress disorder. Psychiatry Res. 2015;229( 1–2):365–369. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26160204
   Google Scholar
• Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience. 2006;139(3):991–997. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16527422
   Google Scholar
• Matsuoka Y, Nishi D, Yonemoto N, et al. Potential role of brain-derived neurotrophic factor in omega-3 Fatty Acid supplementation to prevent posttraumatic distress after accidental injury: an open-label pilot study. Psychother Psychosom. 2011;80(5):310–312. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21720194
   Google Scholar
• Matsumura K, Noguchi H, Nishi D, et al. Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of post-traumatic stress disorder in accident survivors: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2016. DOI:10.1016/j.jad.2016.05.054
   PubMedGoogle Scholar
• Ranieri R, Marasco D, Bifulco M, et al. Phytocannabinoids and cannabimimetic drugs: recent patents in central nervous system disorders. Recent Pat CNS Drug Discov. 2016;10:157–177. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27334611
   PubMedGoogle Scholar
• Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12:825–836. DOI:10.1007/s13311-015-0387-1
   PubMed Web of Science ®Google Scholar
• Trezza V, Campolongo P. The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front Behav Neurosci. 2013;7:100. DOI:10.3389/fnbeh.2013.00100
   PubMed Web of Science ®Google Scholar
• Neumeister A, Seidel J, Ragen BJ, et al. Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder. Psychoneuroendocrinology. 2015;51:577–584. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25456347
   Google Scholar
• Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–534. Available from: http://www.nature.com/doifinder/10.1038/nature00839
   PubMed Web of Science ®Google Scholar
• Korem N, Zer-Aviv TM, Ganon-Elazar E, et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016;27(3):193–202. DOI:10.1515/jbcpp-2015-0058
   PubMedGoogle Scholar
• Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31(12):2652–2659. DOI:10.1038/sj.npp.1301061
   PubMed Web of Science ®Google Scholar
• Foa EB, McLean CP. The efficacy of exposure therapy for anxiety-related disorders and its underlying mechanisms: the case of OCD and PTSD. Annu Rev Clin Psychol. 2016;12:1–28. DOI:10.1146/annurev-clinpsy-021815-093533
   PubMed Web of Science ®Google Scholar
• Hofmann SG. D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety. 2014;31(3):175–177. DOI:10.1002/da.22257
   PubMed Web of Science ®Google Scholar
• McGuire JF, Wu MS, Piacentini J, et al. A meta-analysis of d-cycloserine in exposure-based treatment: moderators of treatment efficacy, response, and diagnostic remission. J Clin Psychiatry. 2016. DOI:10.4088/JCP.15r10334
   PubMedGoogle Scholar
• Ori R, Amos T, Bergman H, et al. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. Cochrane Database Syst Rev. 2015;5:CD007803. DOI:10.1002/14651858.CD007803.pub2
   Google Scholar
• Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry. 2016;3(5):481–488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27067625
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439–452. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20643699
   Google Scholar
• Carhart-Harris RL, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200(3):238–244. DOI:10.1192/bjp.bp.111.103309
   PubMed Web of Science ®Google Scholar
• Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. J psychopharmacol. 2016;30(7):595–600. doi:10.1177/0269881116642542.
   PubMed Web of Science ®Google Scholar
• Sabban EL, Alaluf LG, Serova LI. Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder. Neuropeptides. 2016;56:19–24. DOI:10.1016/j.npep.2015.11.004
   PubMed Web of Science ®Google Scholar
• Adhikari A, Lerner TN, Finkelstein J, et al. Basomedial amygdala mediates top-down control of anxiety and fear. Nature. 2015;527(7577):179–185. doi:10.1038/nature15698
   PubMed Web of Science ®Google Scholar
• Chen Y, Li X, Kobayashi I, et al. Expression and methylation in posttraumatic stress disorder and resilience; evidence of a role for odorant receptors. Psychiatry Res. 2016;245:36–44. DOI:10.1016/j.psychres.2016.07.045
   PubMed Web of Science ®Google Scholar
• Olff M, Van Zuiden M, Koch SBJ, et al. Intranasal oxytocin: miracle cure after trauma? Eur J Psychotraumatol. 2015;6. DOI:10.3402/ejpt.v6.27631
   Web of Science ®Google Scholar
• De Berardis D, Marini S, Serroni N, et al. Targeting the noradrenergic system in posttraumatic stress disorder: a systematic review and meta-analysis of prazosin trials. Curr Drug Targets. 2015;16(10):1094–1106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25944011
   PubMed Web of Science ®Google Scholar
• Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatry Rep. 2007;9(4):291–300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17880860
   PubMedGoogle Scholar
• Alderman CP, McCarthy LC, Condon JT, et al. Topiramate in combat-related posttraumatic stress disorder. Ann Pharmacother. 2009;43(4):635–641. DOI:10.1345/aph.1L578
   PubMed Web of Science ®Google Scholar
• Yeh MSL, Mari JJ, Costa MCP, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011;17(5):305–310. DOI:10.1111/j.1755-5949.2010.00188.x
   PubMed Web of Science ®Google Scholar
• Krystal JH, Pietrzak RH, Rosenheck RA, et al. Veterans Affairs Cooperative Study #504 Group. Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. J Clin Psychiatry. 2016;77(4):483–491. DOI:10.4088/JCP.14m09585
   PubMed Web of Science ®Google Scholar
• Naylor JC, Kilts JD, Bradford DW, et al. A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military veterans resistant to antidepressant treatment. Int Clin Psychopharmacol. 2015;30(3):167–174. DOI:10.1097/YIC.0000000000000061
   PubMed Web of Science ®Google Scholar
• Weiss T, Skelton K, Phifer J, et al. Posttraumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population. Gen Hosp Psychiatry. 2011;33(2):135–142. DOI:10.1016/j.genhosppsych.2011.01.002
   PubMed Web of Science ®Google Scholar
• Bernardy NC, Friedman MJ. How and why does the pharmaceutical management of PTSD differ between men and women? Expert Opin Pharmacother. 2016;17:1449–1451. DOI:10.1080/14656566.2016.1199686
   PubMed Web of Science ®Google Scholar
• Thomaes K, De Kloet C, Wilker S, et al. Investigating biological traces of traumatic stress in changing societies: challenges and directions from the ESTSS task force on neurobiology. Eur J Psychotraumatol. 2016;7:29453. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26996535
   PubMed Web of Science ®Google Scholar
• Flanagan JC, Korte KJ, Killeen TK, et al. Concurrent treatment of substance use and PTSD. Curr Psychiatry Rep. 2016;18(8):70. doi:10.1007/s11920-016-0709-y.
   PubMed Web of Science ®Google Scholar